Merck Enhances Biosafety Testing Capabilities in Scotland at Glasgow and Stirling Sites with Groundbreaking Investment
Merck's expansion in Scotland at the Glasgow and Stirling sites will result in the creation of approximately 500 new jobs.
Biosafety testing plays a vital role in ensuring drug safety, efficacy, and regulatory compliance during the drug development and manufacturing process.
The expansion includes the establishment of a new facility in Glasgow, covering an area of 1,200 square meters, which will house molecular biology and sequencing services.
Merck will also expand the testing capacity in its existing buildings, incorporating biosafety testing, analytical development, and viral clearance suites.
With this expansion, Merck's workforce across the two sites in Scotland will exceed 1,200 employees.
The biosafety testing services at Merck's Glasgow and Stirling sites have demonstrated strong, double-digit growth over several years.
This expansion demonstrates Merck's commitment to being a leading provider of biosafety testing services and meeting the increasing demands of the industry.